Archived Press Releases
12.17.09 Regulus Therapeutics Receives Exclusive License for Intellectual Property on Immuno-inflammatory microRNAs from the California Institute of Technology
12.14.09 Year in Review and a Look Ahead Webinar-Replay
12.09.09 Regulus Therapeutics Inc. presents: “MicroRNA: The Year in Review and a Look Ahead”
10.28.09 Regulus Announces U.S. Allowance of Fundamental microRNA Therapeutics Patent Application
09.17.09 Regulus, Alnylam, and Isis Announce First microRNA Patent Grant in Japan from Tuschl III Patent Series
09.16.09 Regulus Therapeutics Appoints Hubert C. Chen, M.D., Vice President of Translational Medicine
08.11.09 Alnylam and Regulus Receive Notice of Allowance from United States Patent and Trademark Office for New Patent Covering microRNA Therapeutics
05.14.09 Regulus Therapeutics Achieves Initial Milestone in its Inflammatory Diseases Collaboration with GlaxoSmithKline
03.04.09 Regulus Therapeutics Receives $20 Million in a Series A Equity Financing
